HTBT

About:

HTBT is a biopharmaceutical manufacturer that focuses on international biotechnology introduction and absorption.

Top Investors: Shanda Capital, Haoshi Touzi, Shanghai Guxin Touzi, Sinopharm Holding GuoDa Drug Store Co., Kashen Kaize Chuangtou

Description:

HTBT is an enterprise dedicated to the introduction and research and development of diabetes series products and technologies, the construction of industrial clusters of protein oral drug delivery platforms, and the provision of full-course management services for diabetic patients. With flagship goods such oral insulin capsules, recombinant human insulin, insulin analogs, and GLP-1, HTBT aims to establish itself as a credible and reliable biopharmaceutical company and a global biopharmaceutical product R&D and production base (GLP-1 receptor agonists).

Total Funding Amount:

213M CNY

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hefei, Anhui, China

Founded Date:

2007-10-26

Contact Email:

tianmai(AT)htbt.com.cn

Founders:

Xiaoming Gao

Number of Employees:

101-250

Last Funding Date:

2016-12-21

IPO Status:

Private

Industries: